{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:24:19Z","timestamp":1791923059091,"version":"4.3.4"},"reference-count":44,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.1620\/tjem.2025.j049","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T18:07:07Z","timestamp":1746641227000},"page":"55-64","source":"Crossref","is-referenced-by-count":2,"title":["Oxymatrine Inhibits PKM2-Mediated Glycolysis and Enhances Cisplatin Sensitivity in Bladder Cancer"],"prefix":"10.1620","volume":"269","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Ancey, P.B., Contat, C.&Meylan, E. (2018) Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J.<\/i>, 285, 2926-2943. https:\/\/doi.org\/10.1111\/febs.14577","DOI":"10.1111\/febs.14577"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bose, S.&Le, A. (2018) Glucose Metabolism in Cancer. Adv. Exp. Med. Biol.<\/i>, 1063, 3-12. https:\/\/doi.org\/10.1007\/978-3-319-77736-8_1","DOI":"10.1007\/978-3-319-77736-8_1"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Chen, C., Bai, L., Cao, F., Wang, S., He, H., Song, M., Chen, H., Liu, Y., Guo, J., Si, Q., Pan, Y., Zhu, R., Chuang, T.H., Xiang, R.&Luo, Y. (2019a) Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis. Oncogene<\/i>, 38, 4527-4539. https:\/\/doi.org\/10.1038\/s41388-019-0735-4","DOI":"10.1038\/s41388-019-0735-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chen, J., Cao, L., Li, Z.&Li, Y. (2019b) SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. Hum. Cell<\/i>, 32, 193-201. https:\/\/doi.org\/10.1007\/s13577-019-00237-5","DOI":"10.1007\/s13577-019-00237-5"},{"key":"5","doi-asserted-by":"publisher","unstructured":"Chen, K., Zhu, P., Ye, J., Liao, Y., Du, Z., Chen, F., Juanjuan, H., Zhang, S.&Zhai, W. (2019c) Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2\/-9 via regulating p38 signaling pathway. J. Cancer<\/i>, 10, 5397-5403. https:\/\/doi.org\/10.7150\/jca.32875","DOI":"10.7150\/jca.32875"},{"key":"6","doi-asserted-by":"publisher","unstructured":"da Costa, J.B., Gibb, E.A., Nykopp, T.K., Mannas, M., Wyatt, A.W.&Black, P.C. (2022) Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urol. Oncol.<\/i>, 40, 287-294. https:\/\/doi.org\/10.1016\/j.urolonc.2018.11.015","DOI":"10.1016\/j.urolonc.2018.11.015"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Dai, Y., Liu, Y., Li, J., Jin, M., Yang, H.&Huang, G. (2022) Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway. Bioengineered<\/i>, 13, 13906-13918. https:\/\/doi.org\/10.1080\/21655979.2022.2086378","DOI":"10.1080\/21655979.2022.2086378"},{"key":"8","doi-asserted-by":"publisher","unstructured":"Dobruch, J.&Oszczud\u0142owski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina<\/i> (Kaunas<\/i>), 57, 749. https:\/\/doi.org\/10.3390\/medicina57080749","DOI":"10.3390\/medicina57080749"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Han, C., Wang, Z., Chen, S., Li, L., Xu, Y., Kang, W., Wei, C., Ma, H., Wang, M.&Jin, X. (2021) Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS\/NF-kappaB Axis. Oxid. Med. Cell. Longev.<\/i>, 2021, 8851763. https:\/\/doi.org\/10.1155\/2021\/8851763","DOI":"10.1155\/2021\/8851763"},{"key":"10","doi-asserted-by":"publisher","unstructured":"Hu, H., Tu, W., Chen, Y., Zhu, M., Jin, H., Huang, T., Zou, Z.&Xia, Q. (2020) The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients. J. Cancer<\/i>, 11, 2022-2031. https:\/\/doi.org\/10.7150\/jca.38981","DOI":"10.7150\/jca.38981"},{"key":"11","doi-asserted-by":"publisher","unstructured":"Huang, C., Huang, Z., Bai, P., Luo, G., Zhao, X.&Wang, X. (2018a) Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis. OncoTargets Ther.<\/i>, 11, 2075-2082. https:\/\/doi.org\/10.2147\/OTT.S152999","DOI":"10.2147\/OTT.S152999"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Huang, Y., Zhang, J., Wang, G., Chen, X., Zhang, R., Liu, H.&Zhu, J. (2018b) Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2\/STAT3 pathway. Int. J. Immunopathol. Pharmacol.<\/i>, 32, 2058738418781634. https:\/\/doi.org\/10.1177\/2058738418781634","DOI":"10.1177\/2058738418781634"},{"key":"13","doi-asserted-by":"publisher","unstructured":"Icard, P., Shulman, S., Farhat, D., Steyaert, J.M., Alifano, M.&Lincet, H. (2018) How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist. Updat.<\/i>, 38, 1-11. https:\/\/doi.org\/10.1016\/j.drup.2018.03.001","DOI":"10.1016\/j.drup.2018.03.001"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Iqbal, M.A., Gupta, V., Gopinath, P., Mazurek, S.&Bamezai, R.N. (2014) Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett.<\/i>, 588, 2685-2692. https:\/\/doi.org\/10.1016\/j.febslet.2014.04.011","DOI":"10.1016\/j.febslet.2014.04.011"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Jiang, M., Wu, Y., Qi, L., Li, L., Song, D., Gan, J., Li, Y., Ling, X.&Song, C. (2021) Dihydroartemisinin mediating PKM2-caspase-8\/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma. Chem. Biol. Interact.<\/i>, 350, 109704. https:\/\/doi.org\/10.1016\/j.cbi.2021.109704","DOI":"10.1016\/j.cbi.2021.109704"},{"key":"16","doi-asserted-by":"publisher","unstructured":"Jiang, Y., Li, X., Yang, W., Hawke, D.H., Zheng, Y., Xia, Y., Aldape, K., Wei, C., Guo, F., Chen, Y.&Lu, Z. (2014) PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell<\/i>, 53, 75-87. https:\/\/doi.org\/10.1016\/j.molcel.2013.11.001","DOI":"10.1016\/j.molcel.2013.11.001"},{"key":"17","doi-asserted-by":"publisher","unstructured":"Jin, Y., Liu, J., Liu, Y., Liu, Y., Guo, G., Yu, S.&An, R. (2020) Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing beta-Catenin Expression. Front. Pharmacol.<\/i>, 11, 808. https:\/\/doi.org\/10.3389\/fphar.2020.00808","DOI":"10.3389\/fphar.2020.00808"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Jung, Y.Y., Shanmugam, M.K., Narula, A.S., Kim, C., Lee, J.H., Namjoshi, O.A., Blough, B.E., Sethi, G.&Ahn, K.S. (2019) Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model. Cancers<\/i> (Basel<\/i>), 11, 49. https:\/\/doi.org\/10.3390\/cancers11010049","DOI":"10.3390\/cancers11010049"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Li, J., Liu, Z.Y., Yu, H.B., Xue, Q.&Qu, X.S. (2020a) Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells: A protocol of systematic review and meta-analysis. Medicine<\/i> (Baltimore<\/i>), 99, e20181. https:\/\/doi.org\/10.1097\/MD.0000000000020181","DOI":"10.1097\/MD.0000000000020181"},{"key":"20","doi-asserted-by":"publisher","unstructured":"Li, S., Zhang, H., Jiao, Y., Song, X., Wei, L.&Liu, X. (2022) Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460\/miR-197-3p\/ribonucleotide reductase subunit M2 (RRM2). Bioengineered<\/i>, 13, 12912-12926. https:\/\/doi.org\/10.1080\/21655979.2022.2078943","DOI":"10.1080\/21655979.2022.2078943"},{"key":"21","doi-asserted-by":"publisher","unstructured":"Li, S., Zhang, Y., Liu, Q., Zhao, Q., Xu, L., Huang, S., Huang, S.&Wei, X. (2017) Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest. Oncol Lett.<\/i>, 13, 4453-4458. https:\/\/doi.org\/10.3892\/ol.2017.6013","DOI":"10.3892\/ol.2017.6013"},{"key":"22","doi-asserted-by":"publisher","unstructured":"Li, T.E., Wang, S., Shen, X.T., Zhang, Z., Chen, M., Wang, H., Zhu, Y., Xu, D., Hu, B.Y., Wei, R., Zheng, Y., Dong, Q.Z.&Qin, L.X. (2020b) PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Front. Immunol.<\/i>, 11, 589997. https:\/\/doi.org\/10.3389\/fimmu.2020.589997","DOI":"10.3389\/fimmu.2020.589997"},{"key":"23","doi-asserted-by":"publisher","unstructured":"Li, W., Yu, X., Tan, S., Liu, W., Zhou, L.&Liu, H. (2018) Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway. Cancer Med.<\/i>, 7, 208-218. https:\/\/doi.org\/10.1002\/cam4.1269","DOI":"10.1002\/cam4.1269"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Li, X., Sun, J., Xu, Q., Duan, W., Yang, L., Wu, X., Lu, G., Zhang, L.&Zheng, Y. (2020c) Oxymatrine Inhibits Colorectal Cancer Metastasis via Attenuating PKM2-Mediated Aerobic Glycolysis. Cancer Manag. Res.<\/i>, 12, 9503-9513. https:\/\/doi.org\/10.2147\/CMAR.S267686","DOI":"10.2147\/CMAR.S267686"},{"key":"25","doi-asserted-by":"publisher","unstructured":"Liang, L., Wu, J., Luo, J., Wang, L., Chen, Z.X., Han, C.L., Gan, T.Q., Huang, J.A.&Cai, Z.W. (2020) Oxymatrine reverses 5-fluorouracil resistance by inhibition of colon cancer cell epithelial-mesenchymal transition and NF-kappaB signaling in vitro. Oncol. Lett.<\/i>, 19, 519-526. https:\/\/doi.org\/10.3892\/ol.2019.11090","DOI":"10.3892\/ol.2019.11090"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Lima, A.P.B., Almeida, T.C., Barros, T.M.B., Rocha, L.C.M., Garcia, C.C.M.&da Silva, G.N. (2020) Toxicogenetic and antiproliferative effects of chrysin in urinary bladder cancer cells. Mutagenesis, geaa021. https:\/\/doi.org\/10.1093\/mutage\/geaa021","DOI":"10.1093\/mutage\/geaa021"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Ling, Q., Xu, X., Wei, X., Wang, W., Zhou, B., Wang, B.&Zheng, S. (2011) Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J. Exp. Clin. Cancer Res.<\/i>, 30, 66. https:\/\/doi.org\/10.1186\/1756-9966-30-66","DOI":"10.1186\/1756-9966-30-66"},{"key":"28","doi-asserted-by":"publisher","unstructured":"Liu, J., Yao, Y., Ding, H.&Chen, R. (2014) Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3\/caspase-9 pathway in human leukemia HL-60 cells. Tumour Biol.<\/i>, 35, 5409-5415. https:\/\/doi.org\/10.1007\/s13277-014-1705-7","DOI":"10.1007\/s13277-014-1705-7"},{"key":"29","doi-asserted-by":"publisher","unstructured":"Malats, N.&Real, F.X. (2015) Epidemiology of bladder cancer. Hematol. Oncol. Clin. North Am., 29, 177-189, vii. https:\/\/doi.org\/10.1016\/j.hoc.2014.10.001","DOI":"10.1016\/j.hoc.2014.10.001"},{"key":"30","doi-asserted-by":"publisher","unstructured":"Shangguan, C., Gan, G., Zhang, J., Wu, J., Miao, Y., Zhang, M., Li, B.&Mi, J. (2018) Cancer-associated fibroblasts enhance tumor (18)F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics<\/i>, 8, 1376-1388. https:\/\/doi.org\/10.7150\/thno.22717","DOI":"10.7150\/thno.22717"},{"key":"31","doi-asserted-by":"publisher","unstructured":"Shin, S.S., Park, Y.J., Hwang, B., Park, S.L., Han, S.W., Park, S.S., Choi, Y.H., Kim, W.J.&Moon, S.K. (2019) Triacanthine exerts antitumor effects on bladder cancer in vitro and in vivo. Phytomedicine<\/i>, 64, 153069. https:\/\/doi.org\/10.1016\/j.phymed.2019.153069","DOI":"10.1016\/j.phymed.2019.153069"},{"key":"32","doi-asserted-by":"publisher","unstructured":"Suh, H.N.&Han, H.J. (2013) Fibronectin-induced VEGF receptor and calcium channel transactivation stimulate GLUT-1 synthesis and trafficking through PPARgamma and TC10 in mouse embryonic stem cells. Stem Cell Res.<\/i>, 10, 371-386. https:\/\/doi.org\/10.1016\/j.scr.2013.01.008","DOI":"10.1016\/j.scr.2013.01.008"},{"key":"33","doi-asserted-by":"publisher","unstructured":"Sun, K., Tang, S., Hou, Y., Xi, L., Chen, Y., Yin, J., Peng, M., Zhao, M., Cui, X.&Liu, M. (2019) Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling. EBioMedicine<\/i>, 41, 370-383. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.025","DOI":"10.1016\/j.ebiom.2019.02.025"},{"key":"34","doi-asserted-by":"publisher","unstructured":"Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A.&Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.<\/i>, 71, 209-249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"35","doi-asserted-by":"publisher","unstructured":"Wang, J.Z., Zhu, W., Han, J., Yang, X., Zhou, R., Lu, H.C., Yu, H., Yuan, W.B., Li, P.C., Tao, J., Lu, Q., Wei, J.F.&Yang, H. (2021) The role of the HIF-1alpha\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun<\/i>. (Lond<\/i>.), 41, 560-575. https:\/\/doi.org\/10.1002\/cac2.12158","DOI":"10.1002\/cac2.12158"},{"key":"36","doi-asserted-by":"publisher","unstructured":"Wang, W., You, R.L., Qin, W.J., Hai, L.N., Fang, M.J., Huang, G.H., Kang, R.X., Li, M.H., Qiao, Y.F., Li, J.W.&Li, A.P. (2015) Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacol. Sin.<\/i>, 36, 676-679. https:\/\/doi.org\/10.1038\/aps.2015.24","DOI":"10.1038\/aps.2015.24"},{"key":"37","doi-asserted-by":"publisher","unstructured":"Wang, Y., Hao, F., Nan, Y., Qu, L., Na, W., Jia, C.&Chen, X. (2018) PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. Int. J. Biol. Sci.<\/i>, 14, 1883-1891. https:\/\/doi.org\/10.7150\/ijbs.27854","DOI":"10.7150\/ijbs.27854"},{"key":"38","unstructured":"Xie, W., Zhang, Y., Zhang, S., Wang, F., Zhang, K., Huang, Y., Zhou, Z., Huang, G.&Wang, J. (2019) Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt\/beta-Catenin signaling pathway. Am. J. Cancer Res.<\/i>, 9, 1796-1814."},{"key":"39","doi-asserted-by":"publisher","unstructured":"Yamazaki, M.(2000) The pharmacological studies on matrine and oxymatrine. Yakugaku Zasshi<\/i>, 120, 1025-1033. https:\/\/doi.org\/10.1248\/yakushi1947.120.10_1025","DOI":"10.1248\/yakushi1947.120.10_1025"},{"key":"40","doi-asserted-by":"publisher","unstructured":"Yang, J., Ren, B., Yang, G., Wang, H., Chen, G., You, L., Zhang, T.&Zhao, Y. (2020) The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell. Mol. Life Sci.<\/i>, 77, 305-321. https:\/\/doi.org\/10.1007\/s00018-019-03278-z","DOI":"10.1007\/s00018-019-03278-z"},{"key":"41","doi-asserted-by":"publisher","unstructured":"Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W.K.&Lu, Z. (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell<\/i>, 150, 685-696. https:\/\/doi.org\/10.1016\/j.cell.2012.07.018","DOI":"10.1016\/j.cell.2012.07.018"},{"key":"42","doi-asserted-by":"publisher","unstructured":"Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K.&Lu, Z. (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature<\/i>, 480, 118-122. https:\/\/doi.org\/10.1038\/nature10598","DOI":"10.1038\/nature10598"},{"key":"43","doi-asserted-by":"publisher","unstructured":"Yang, X., Cheng, Y., Li, P., Tao, J., Deng, X., Zhang, X., Gu, M., Lu, Q.&Yin, C. (2015) A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN\/PI3K\/AKT\/mTOR axis. Tumour Biol.<\/i>, 36, 383-391. https:\/\/doi.org\/10.1007\/s13277-014-2617-2","DOI":"10.1007\/s13277-014-2617-2"},{"key":"44","doi-asserted-by":"publisher","unstructured":"Zhu, S., Guo, Y., Zhang, X., Liu, H., Yin, M., Chen, X.&Peng, C. (2021) Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett.<\/i>, 503, 240-248. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.018","DOI":"10.1016\/j.canlet.2020.11.018"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/1\/269_2025.J049\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:21:48Z","timestamp":1780716108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/1\/269_2025.J049\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2025.j049","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025.J049"}}